Myriad Genetics (MYGN) Research & Development (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Research & Development data on file, last reported at $27.1 million in Q1 2026.

• Research & Development for Q1 2026 came in at $27.1 million, down 1.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.4 million (down 7.72% YoY), and the FY2025 annual result was $106.8 million, down 5.82% from the prior year.
• Research & Development grew to $27.1 million in Q1 2026 per MYGN's latest filing, from $25.5 million in the prior quarter.
• Over five years, Research & Development peaked at $32.2 million in Q4 2024 and troughed at $20.3 million in Q2 2022.
• A 5-year average of $24.7 million and a median of $24.9 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development soared 53.33% in 2024, then fell 20.81% in 2025.
• A 5-year view of Research & Development shows it stood at $23.4 million in 2022, then decreased by 10.26% to $21.0 million in 2023, then jumped by 53.33% to $32.2 million in 2024, then slipped by 20.81% to $25.5 million in 2025, then rose by 6.27% to $27.1 million in 2026.
• Business Quant data shows MYGN's Research & Development at $27.1 million in Q1 2026, $25.5 million in Q4 2025, and $28.2 million in Q3 2025.